Search results for "Anticonvulsants"

showing 10 items of 116 documents

Micellar electrokinetic capillary chromatography for therapeutic drug monitoring of carbamazepine and its main metabolites.

1998

In carbamazepine (CBZ) therapy the concomitant monitoring of concentrations of CBZ and its metabolites is strictly recommended, primarily to avoid toxic side effects. Currently, clinical routine monitoring of CBZ is accomplished by high-performance liquid chromatography or immunological methods. In this study a micellar electrokinetic capillary chromatographic (MECC) method was developed for routine drug monitoring of CBZ and its main metabolites, carbamazepine 10,11-diol and carbamazepine 10,11-epoxide, in human serum or plasma samples. The MECC method enabled baseline separation of all analytes within 2.5 min. The assay revealed sufficient precision and sensitivity and the results of eith…

DrugAnalyteChromatographymedicine.diagnostic_testChemistrymedia_common.quotation_subjectMetabolitemedicine.medical_treatmentElectrophoresis CapillaryGeneral ChemistryCarbamazepineHigh-performance liquid chromatographyMicellar electrokinetic chromatographychemistry.chemical_compoundAnticonvulsantCarbamazepineTherapeutic drug monitoringmedicineHumansAnticonvulsantsDrug MonitoringChromatography High Pressure Liquidmedia_commonmedicine.drugJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Carbamazepine transbuccal delivery: the histo-morphological features of reconstituted human oral epithelium and buccal porcine mucosae in the transmu…

2009

Transbuccal drug delivery is an attractive way of administration since several well-known advantages are provided, especially with respect to peroral management. Carbamazepine (CBZ) is an anticonvulsant which is useful in controlling neuropathic pain, and it is currently administered by peroral route, although its absorption and bioavailability is limited due to various factors. The oral cavity could be an interesting site for transbuccal CBZ delivery due to two properties: slow administration of constant low drug doses and less dose-related side effects. However, in transbuccal absorption a major limitation could be the low permeability of the mucosa which results in low drug bioavailabil…

DrugSwinemedicine.medical_treatmentmedia_common.quotation_subjectImmunologyAbsorption (skin)PharmacologyPermeabilitymedicineImmunology and AllergyAnimalsHumansmedia_commonPharmacologyChemistryMouth MucosaCarbamazepineBuccal administrationEpitheliumCarbamazepine Transbuccal drug delivery Porcine buccal mucosa Reconstituted human oral epithelium Trigeminal neuralgiaBioavailabilityAnticonvulsantmedicine.anatomical_structureCarbamazepineCheekDrug deliveryAnticonvulsantsmedicine.drugInternational journal of immunopathology and pharmacology
researchProduct

Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate.

2007

Hemicrania continua (HC) is an uncommon and under-recognized primary headache disorder characterized by a strictly unilateral continuous headache of moderate intensity with possible exacerbations and associated with ipsilateral autonomic features. HC has generally a prompt and enduring response to indomethacin although 25% to 50% of treated patients develop gastrointestinal side effects. These cases pose a difficult management challenge as no other drug is consistently effective in HC. Recently 2 HC patients responsive to topiramate treatment have been reported. Here we describe 2 more patients effectively treated with topiramate. Neither reported any side effects and one had persisting res…

DrugTopiramateAdultmedia_common.quotation_subjectmedicine.medical_treatmentIndomethacinNeurological disorderFructoseCentral nervous system diseaseDrug withdrawalPrimary headacheTopiramateProfilaxismedicineHumansmedia_commonbusiness.industryAnti-Inflammatory Agents Non-SteroidalHeadacheHemicrania continuaMiddle Agedmedicine.diseaseAnticonvulsantNeurologyHemicrania continuaAnesthesiaGastritisRetreatmentSettore MED/26 - NeurologiaAnticonvulsantsFemaleNeurology (clinical)businessmedicine.drugHeadache
researchProduct

Rash and multiorgan dysfunction following lamotrigine: could genetic be involved?

2015

We report the case of a 38-year-old woman treated with lamotrigine who experienced multi-organ dysfunction. The patient received the drug at the dose of 100 mg per day. One week later, the treatment was suspended because of an extensive body rash. Twenty-four hours later, the patient appeared drowsy and stuporous and was hospitalized. On the fifth day, the patient was admitted with a clinical picture of acute multi-organ failure in our Institute, where, she, despite the support of vital functions with vasoactive drugs, continuous hemofiltration and ventilation with oxygen, died. Serum lamotrigine concentration was measured 110 h after its last dose and the drug resulted to be still present …

DrugUGT1A4Genotypemedia_common.quotation_subjectMultiple Organ FailurePharmaceutical ScienceSNPPharmacyLamotrigineToxicologyLamotriginePolymorphism Single NucleotideVasoactiveRashmedicineHumansPharmacology (medical)GlucuronosyltransferaseUGT2B7media_commonPharmacologybusiness.industryTriazinesPharmacogeneticMultiorgan dysfunctionABCB1ExanthemaRashHLAMulti-organ dysfunctionAnesthesiaBreathingSettore BIO/14 - FarmacologiaAnticonvulsantsFemaleUGT1A4medicine.symptombusinessPharmacogeneticsAntiepileptic drugmedicine.drug
researchProduct

Calixarene: A Versatile Material for Drug Design and Applications

2016

The therapy of various diseases by the drugs entrapped in calixarene derivatives is gaining attraction of researchers nowadays. Calixarenes are macrocyclic nano-baskets which belong to cavitands class of host-guest chemistry. They are the marvelous hosts with distinct hydrophobic three dimensional cavities to entrap and encapsulate biologically active guest drugs. Calixarene and its derivatives develop inclusion complexes with various types of drugs and vitamins for their sustained/targeted release. Calixarene and its derivatives are used as carriers for anti-cancer, anti-convulsant, anti-hypertensive, anthelmentic, anti-inflammatory, antimicrobial and antipsychotic drugs. They are the impo…

Drugmedia_common.quotation_subjectAnti-Inflammatory AgentsSupramolecular chemistrymacromolecular substances010402 general chemistry01 natural sciencesAnti-Infective AgentsDrug DiscoveryCalixareneHumansOrganic chemistryProdrugsAntihypertensive AgentsTargeted releasemedia_commonAnthelminticsPharmacologyDrug Carriers010405 organic chemistryChemistryProdrugBiocompatible material0104 chemical sciencesDrug DesignDrug releaseAnticonvulsantsCalixarenesAntipsychotic AgentsCurrent Pharmaceutical Design
researchProduct

Suppressive Efficacy by a Commercially Available Blue Lens on PPR in 610 Photosensitive Epilepsy Patients

2006

Purpose Photosensitivity can represent a serious problem in epilepsy patients, also because pharmacologic treatment is often ineffective. Nonpharmacologic treatment using blue sunglasses is effective and safe in controlling photosensitivity, but large series of patients have never been studied. Methods This multicenter study was conducted in 12 epilepsy centers in northern, central, southern, and insular Italy. A commercially available lens, named Z1, obtained in a previous trial, was used to test consecutively enrolled pediatric and adult epilepsy patients with photosensitivity. Only type 4 photosensitivity (photoparoxysmal response, PPR) was considered in the study. A standardized method …

EPILEPSY-PHOTOSENSITIVE-BLUE GLASSES-NONPHARMACOLOGICAdultMalemedicine.medical_specialtyAdolescentEpilepsy ReflexPharmacological treatmentCentral nervous system diseaseEpilepsyPhotosensitive epilepsyInternal medicineFemale patientmedicineHumansPractice Patterns Physicians'ChildAgedbusiness.industryVideotape RecordingLarge seriesElectroencephalographyMiddle Agedmedicine.diseaseTREATMENT-PHOTOPAROXYSMAL RESPONSE-PPRSurgeryClinical trialTreatment OutcomeItalyNeurologyMulticenter studyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)PHOTOSENSITIVEEye Protective DevicesbusinessColor PerceptionPhotic StimulationEpilepsia
researchProduct

The inhibitory neural circuitry as target of antiepileptic drugs.

2001

Impairments and defects in the inhibitory neurotransmission in the CNS can contribute to various seizure disorders, i.e., gamma-aminobutyric acid (GABA) and glycine as the main inhibitory neurotransmitters in the brain play a crucial role in some forms of epilepsy. Recent advances in deciphering the molecular basis of the GABAergic and glycinergic systems has been achieved by means of cloning techniques and gene targeting strategies in animals, contributing to the understanding of drug action. As well, several anticonvulsive substances emerged which target key molecules of the inhibitory systems. Employment of recombinant expression systems, including, but not restricted to the inhibitory c…

GABA Plasma Membrane Transport ProteinsGABA Plasma Membrane Transport ProteinsOrganic Anion TransportersDrug actionPharmacologyNeurotransmissionBiologyInhibitory postsynaptic potentialBiochemistrySynaptic TransmissionGABA AntagonistsEpilepsyDrug DiscoverymedicineAnimalsHumansGlycine receptorgamma-Aminobutyric AcidPharmacologyEpilepsyOrganic ChemistryMembrane ProteinsMembrane Transport Proteinsmedicine.diseaseReceptors GABA-AMechanism of actionReceptors GABA-BMolecular MedicineGABAergicAnticonvulsantsmedicine.symptomCarrier ProteinsCurrent medicinal chemistry
researchProduct

Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze.

1999

The behavioural consequences of inhibition of gamma-aminobutyric acid (GABA) uptake were studied. Two GABA uptake inhibitors, tiagabine and SKF 89976-A, were administered to rats, and behaviour was analysed 30 min later in a standard open field, an enriched open field, and an elevated plus-maze. Eight groups of animals received either saline (0.9%), tiagabine, or SKF 89976-A. At a dose of 18.5 mg/kg, tiagabine, an established antiseizure drug, impaired motor coordination, enhanced exploratory activity and reduced anxiety related behaviour. SKF 89976-A exhibited minimal effects over the dose range tested. These results indicate that inhibition of GABA uptake might be a pharmacological strate…

GABA Plasma Membrane Transport ProteinsMaleElevated plus mazeGABA Plasma Membrane Transport ProteinsTiagabineGABA AgentsNipecotic AcidsOrganic Anion TransportersPharmacologyAnxietyEnvironmentMotor Activitygamma-Aminobutyric acidOpen fieldmedicineGABA transporterAnimalsTiagabineGABA Agonistsgamma-Aminobutyric AcidPharmacologybiologyBehavior AnimalDose-Response Relationship DrugChemistryMembrane ProteinsMembrane Transport ProteinsRatsPsychiatry and Mental healthGABA Agentsnervous systembiology.proteinExploratory BehaviorGABA Uptake InhibitorsAnticonvulsantsCarrier Proteinsmedicine.drugBehavioural pharmacology
researchProduct

Carbonyl metallo immuno assay: a new application for Fourier transform infrared spectroscopy

2000

Abstract We describe here the development of a new, non-isotopic immunological assay termed CMIA (carbonyl metallo immunoassay) that uses metal carbonyl complexes as tracers and Fourier transform infrared spectroscopy (FT-IR) as the detection method. This assay is based on the particular spectral features of these complexes, which show very strong absorption bands in the 1800–2200 cm −1 spectral range where proteins and organic molecules do not absorb. In Section 1 , the optimisation of the quantitative detection of these tracers is detailed. In Section 2 , the implementation of mono-CMIA is described, including the CMIA assays of three antiepileptic drugs (carbamazepine, phenobarbital, phe…

ImmunoassayDetection limitChromatographymedicine.diagnostic_testChemistryClinical BiochemistryPharmaceutical ScienceInfrared spectroscopyMetal carbonylCombinatorial chemistryAnalytical Chemistrysymbols.namesakeFourier transformImmunoassaySpectroscopy Fourier Transform InfraredDrug DiscoverymedicinesymbolsAnticonvulsantsFourier transform infrared spectroscopyAbsorption (electromagnetic radiation)Quantitative analysis (chemistry)SpectroscopyJournal of Pharmaceutical and Biomedical Analysis
researchProduct

Production of specific antibodies and development of a non-isotopic immunoassay for carbamazepine by the carbonyl metallo-immunoassay (CMIA) method.

1995

Abstract As part of our ongoing work to extend the range of applications of the non-isotopic carbonyl metalloimmunoassay (CMIA), previously developed in our laboratory, we describe here the first CMIA study of carbamazepine. The CMIA method uses a metal carbonyl complex as a non-isotopic tracer, and in this case we chose to employ the dicobalt hexacarbonyl moiety (Co2(CO)6) attached to an alkyne. Two organometallic tracers, 3 and 7 , were synthesized, differentiated by the nature and length of the spacer arm of the Co2(CO)6 moiety. Two different coupling methods were subsequently used to synthesize the immunogens 1 and 2, the first one used a carbodiimide, while the second, employed dimethy…

ImmunologyAlkyneCross ReactionsBinding Competitivechemistry.chemical_compoundDimethyl AdipimidateAntibody SpecificityDibenzazepinesSpectroscopy Fourier Transform InfraredmedicineOrganometallic CompoundsImmunology and AllergyMoietyAnimalsCarbodiimidechemistry.chemical_classificationAntiserumImmunoassayChromatographymedicine.diagnostic_testCobaltTiterCarbamazepinechemistryDimethyl AdipimidateDicyclohexylcarbodiimideImmunoassayAnticonvulsantsImmunizationRabbitsQuantitative analysis (chemistry)HaptensJournal of immunological methods
researchProduct